Table 3.
Comparison between survivors and non-survivors
| Non-survivors | Survivors | |||
|---|---|---|---|---|
| n = 5 | (%) | n = 11 | (%) | |
| Male | 1 | (20) | 6 | (55) |
| Agea | 66.8 | (46–81) | 79.8 | (51–96) |
| Underlying conditions | ||||
| Serum albumin (g/dL)ab | 2.0 | (1.5–2.6) | 2.4 | (1.1–4.2) |
| HTLV-1c | 3 | (75) | 8 | (80) |
| Steroid user | 2 | (40) | 3 | (27) |
| Anti-cancer drug | 0 | 1 | ||
| Underlying disease | ||||
| Adult T-cell lymphoma/leukemia | 1 | (20) | 4 | (27) |
| Type 2 diabetes mellitus | 2 | (40) | 1 | (9) |
| Cases with pulmonary complication | 5 | (100) | 10 | (91) |
| Acute respiratory distress syndrome | 4 | 4 | ||
| Pulmonary alveolar hemorrhage | 1 | 2 | ||
| Other complication | ||||
| Systemic infection | 5 | (100) | 5 | (45) |
| Sepsis | 4 | 4 | ||
| Meningitis | 3 | 2 | ||
| Ileus | 1 | (20) | 3 | (27) |
Abbreviations: HTLV-1 = human T-cell leukemia virus type 1, amean (range) was used for these values, btotal 13 cases (3 non-survivors and 10 survivors) were tested serum albumin, ctotal 14 cases (4 non-survivors and 10 survivors) were tested HTLV-1